VANCOUVER, British Columbia, July 1, 2004 (PRIMEZONE) -- Dr. John Todd, President of ProtoKinetix, Inc. (OTCBB:PKTX) is indeed privileged to announce Professor Jean-Louis Boitieux's acceptance of a position on the Company's Scientific Advisory Board. Professor Boitieux is a professor at several Universities, and is the Research Director for INSERM (The National Institute of Health and Medical Research). Professor Jean-Louis Boitieux obtained his undergraduate degree from the University of Quebec, followed by a Doctorate of Biology and a Doctorate of State from the University of Sciences and Technology of Compiegne in France. He also received part of his training at the Universities of Arizona and Kansas. He is an active member of the Academy of Science of New York.
Professor Boitieux is a pioneer and a specialist in the field of Immunological Methods and in the Engineering of Antibodies for the cellular recognition of malignant cells using biosensors. This was done in collaboration with the laboratory at Compiegne headed up by the renowned Professor Daniel Thomas. Jean-Louis has authored almost one hundred publications in the fields of clinical biology and in genetic engineering. He holds several patents related to work he has done.
During and after his University career, Dr. Boitieux acquired significant expertise in the development of industrial processes and in the field of technology transfer. This experience was acquired in his role as an advisor to the Director of L'Oreal and as a scientific advisor in The Office of the Ionizing Radiations (ORIS), a subsidiary of the French Commission of Atomic Energy (Commission de l'Energie Atomique).
Dr. Boitieux serves as a Scientific and Technology Representative for the French Government to the European Union in Brussels, an appointment that gives him a European vision of the research that is being conducted, particularly in the field of Biotechnology and Medicine.
The government of France has recently recognized the leadership and accomplishments of Dr. Biotieux by bestowing upon him, through a Presidential decree, the National Order of Merit of France.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission.
On behalf of the Board of Directors, Dr. John Todd, President